BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
June 1, 2006
View Archived Issues
As First Step In Biogeneric Debate, Omnitrope Cleared
The FDA approved the biosimilar product Omnitrope (somatropin [rDNA origin]), a follow-on version of a growth hormone drug, in a landmark decision that reverberated among both supporters and opponents. (BioWorld Today)
Read More
FDA Refuses NDA Filing For RSD1235; Cardiome Plunges
Read More
Cell Growth Kinase Integrates Circulating, Stored Fuel Signal
Read More
Biogen Buying Fumapharm, Consolidating BG-12 Rights
Read More
Isis Gains Flexibility Via $75M Equity Financing Commitment
Read More
Clinic Roundup
Read More
Other News To Note
Read More